Fig. 6

miR-1271 negatively regulates PES1 to impede the development of prostate cancer. PC-3 cells were transfected with sh-PES1 coupled with NC inhibitor or both sh-PESE1 coupled with miR-1271 inhibitor. a miR-1271 expression and PES1 mRNA expression in PC-3 cells detected by RT-qPCR. b Images of EdU assay (200×), positive rate of PC-3 cells as well as the expression of Ki67 and PCNA in PC-3 cells detected by EdU assay and Western blot analysis. c Cell apoptosis and protein expression of c-caspase-3/caspase-3 and c-caspase-9/caspase-9 in PC-3 cells tested by flow cytometry and Western blot analysis. d Images (200 ×) and quantitative analysis of cell migration and invasion and protein expression of MMP-2 and MMP-9 in PC-3 cells evaluated by Transwell assay and Western blot analysis. e miR-1271 expression and PES1 mRNA expression in mouse tumors detected by RT-qPCR. f Representative tumors and tumor growth rate of mice bearing human prostate cancer cell xenografts in response to co-treatment of sh-PES1 and NC antagomir or co-treatment of sh-PES1 and miR-1271 antagomir (n = 6 for each group). *p < 0.05, vs. co-treatment of sh-NC and NC inhibitor or co-treatment of sh-NC and NC antagomir; #p < 0.05, vs. co-treatment of sh-PES1 and NC inhibitor or co-treatment of sh-PES1 and NC antagomir. Data obtained from three independent experiments were presented as mean ± standard deviation and tested using one-way ANOVA among multiple groups. Tumor size over indicated time points was compared using two-way ANOVA